Daniel Bauer, MD, PhD
Disclosures: Consulting Fee-Sanofi|Consulting Fee-Tome|Royalties or Patent Beneficiary-CRISPR Therapeutics - 02/24/2022

Daniel E. Bauer, MD PhD


Daniel Bauer is a physician-scientist whose research focuses on functional genomics to dissect determinants of blood cell development and disease and develop innovative therapies. His clinical work is in pediatric hematology. He identified the BCL11A erythroid enhancer as a favorable target for therapeutic genome editing for the β-hemoglobinopathies, now being investigated in several clinical trials. His research has elucidated molecular mechanisms of hemoglobin switching; advanced high-throughput gene editing approaches to associate genetic variants with phenotypes; and developed methods for highly efficient and specific gene editing in human hematopoietic stem cells. He is a Principal Investigator, Staff Physician, and Director of the Gene Therapy Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Associate Professor of Pediatrics at Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and Associate Member of the Broad Institute of MIT and Harvard. He was recipient of the NIH Director’s New Innovator Award (National Institutes of Health 2016), Young Investigator Award (Society for Pediatric Research 2017), and Outstanding New Investigator Award (American Society of Gene and Cell Therapy 2020).